Evidence map›Paper›PMID 38263350›Full record

ArticleScientific reports2024

Hyperoxia prevents the dynamic neonatal increases in lung mesenchymal cell diversity.

Fabio Zanini, Xibing Che, Nina E Suresh, Carsten Knutsen, Paula Klavina, Yike Xie, Racquel Domingo-Gonzalez, Min Liu, Alexander Kum, Robert C Jones and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Fabio ZaniniSchool of Clinical Medicine, University of New South Wales, Sydney, Australia. fabio.zanini@unsw.edu.au.
Xibing CheCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
Nina E SureshCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
Carsten KnutsenCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
Paula KlavinaSchool of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
Yike XieSchool of Clinical Medicine, University of New South Wales, Sydney, Australia.
Racquel Domingo-GonzalezCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
Min LiuCenter for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
Alexander Kum *Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
Robert C JonesDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Stephen R Quake *Department of Bioengineering, Stanford University, Stanford, CA, USA.
Cristina M Alvira *Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA.
David N Cornfield *Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA, USA. davidco@stanford.edu.
Stanford University · USUNSW Sydney · AUChan Zuckerberg Initiative (United States) · USTrinity College Dublin · IE

Funding

Stanford Training Program in Lung BiologyT32HL129970 · NHLBI · STANFORD UNIVERSITY · PI CORNFIELD, DAVID N., NICOLLS, MARK ROBERT · 2016 to 2025
$3.2M
Developmental Heterogeneity of Pulmonary Endothelial Phenotype at Single Cell ResolutionR01HL154002 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALVIRA, CRISTINA MARIA · 2021 to 2024
$2.8M
Novel pathways regulating calcium mediated contractility in the pregnant uterusR01HD092316 · NICHD · STANFORD UNIVERSITY · PI ALVIRA, CRISTINA MARIA, CORNFIELD, DAVID N. · 2018 to 2022
$2.7M
Diverse Homeostatic Roles for Distinct Macrophages in the Developing Lung VasculatureR01HL155828 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALVIRA, CRISTINA MARIA · 2021 to 2024
$2.6M
Pericytes and postnatal alveolarization: Role of hypoxia inducible factorsR01HL160018 · NHLBI · STANFORD UNIVERSITY · PI ALVIRA, CRISTINA MARIA, CORNFIELD, DAVID N. · 2022 to 2025
$2.6M
Novel Molecular Mechanisms Regulating Postnatal Pulmonary AngiogenesisR01HL122918 · NHLBI · STANFORD UNIVERSITY · PI ALVIRA, CRISTINA MARIA · 2014 to 2018
$2.3M
DEVELOPMENTAL REGULATION OF OXYGEN SENSING IN THE LUNGR01HL060784 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CORNFIELD, DAVID N. · 1999 to 2009
$2.2M
BD Canto II RUO CytometerS10RR027431 · NCRR · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2010 to 2010
$236k
STRONG HEART STUDY ANALYSES OBESITY AND LIPOPROTEINSR03HL060018 · NHLBI · MEDSTAR RESEARCH INSTITUTE · PI HANNAH, JUDY S · 1998 to 1998
–
NCRR NIH HHS S10 RR027431NHLBI NIH HHS 060784NHLBI NIH HHS 122918NHLBI NIH HHS 5T32HL129970NHLBI NIH HHS 60018NHLBI NIH HHS R01 HL154002NHLBI NIH HHS R01 HL155828NHLBI NIH HHS R01 HL160018NHLBI NIH HHS T32 HL129970NICHD NIH HHS R01 HD092316
6 · The paper itself

Abstract

Rapid expansion of the pulmonary microvasculature through angiogenesis drives alveolarization, the final stage of lung development that occurs postnatally and dramatically increases lung gas-exchange surface area. Disruption of pulmonary angiogenesis induces long-term structural and physiologic lung abnormalities, including bronchopulmonary dysplasia, a disease characterized by compromised alveolarization. Although endothelial cells are primary determinants of pulmonary angiogenesis, mesenchymal cells (MC) play a critical and dual role in angiogenesis and alveolarization. Therefore, we performed single cell transcriptomics and in-situ imaging of the developing lung to profile mesenchymal cells during alveolarization and in the context of lung injury. Specific mesenchymal cell subtypes were present at birth with increasing diversity during alveolarization even while expressing a distinct transcriptomic profile from more mature correlates. Hyperoxia arrested the transcriptomic progression of the MC, revealed differential cell subtype vulnerability with pericytes and myofibroblasts most affected, altered cell to cell communication, and led to the emergence of Acta1 expressing cells. These insights hold the promise of targeted treatment for neonatal lung disease, which remains a major cause of infant morbidity and mortality across the world.

Indexed as

Bronchopulmonary DysplasiaHyperoxiaMesenchymal Stem CellsEndothelial CellsHumansInfantInfant, NewbornLung

Identifiers

PMID38263350
PMCPMC10805790
OpenAlexW4391133139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.